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Abstract
Introduction Post-mastectomy seroma and related com-
plications are common problems in modern oncological
surgery. Occurrence rates of up to 59 % have been reported
in literature. High-risk patients, that is, those who have
undergone previous surgeries, present with a high body
mass index, have had radiation or chemotherapy, present a
particular challenge. Noninvasive measures such as fibrin-
based sealants have thus far not been able to effectively
reduce complications associated with fluid accumulation. A
recent study using a lysine-derived urethane adhesive
named TissuGlu however, showed promising results in
patients after abdominoplasty.
Methods 32 consecutively recruited patients received a
mastectomy using a gold standard mastectomy technique
as well as TissuGlu flap fixation. A control group of 173
patients, having received a gold standard mastectomy-only,
was analyzed retrospectively, totaling 205 patients. Pri-
mary endpoints were post-discharge seroma formation and
revision surgery/re-hospitalization. Secondary endpoints
were initial seroma volume, postoperative pain, hematoma
formation and day of drain removal.
Results No significant difference in seroma formation
was demonstrated. The revision surgery/re-hospitalization
rate was reduced from 6.9 to 0 %, though this did not reach
significance. Significant improvement could be shown in
the TissuGlu group regarding time to drain removal
(17 % decrease), and hematoma formation (14 % de-
crease). No difference was shown in postoperative pain.
Conclusion Although patient numbers are still small,
advantages in revision surgery/re-hospitalization rate, he-
matoma formation as well as time to drain removal was
shown for the TissuGlu group.
Clinical question/level of evidence Therapeutic, IV.
Keywords Breast cancer  Mastectomy  Seroma 
Prevention  TissuGlu  Drain  Time to drain removal
Introduction
Post-mastectomy seroma and its associated complications
remain problematic in modern oncological surgery [1, 2].
The most common approach for preventing seroma is the
placement of surgical drains within the wound area, though
the efficacy of this approach is not universally acknowl-
edged and the problem persists in spite of the use of drains
[1]. Other approaches have been evaluated to reduce the
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incidence of complications associated with seroma forma-
tion, but a consensus on the best solution remains elusive.
Recent studies aimed at the reduction or elimination of
dead space have shown some promise in reducing these
complications in other surgical techniques. Two options
include the use of progressive tension or quilting suture
techniques and the less invasive application of a lysine-
derived urethane adhesive (TissuGlu, Cohera Medical,
Pittsburgh, PA, USA) [3–7]. Our group already demon-
strated the use of TissuGlu in the successful resolution of
a persistent post-mastectomy seroma [8]. While a plethora
of literature is available on the benefits of post-surgical
drain placement, due to the persistence of the problem
some authors argue that drain placement does not represent
a satisfactory solution and may not be necessary at all [9].
Nonetheless, most surgeons still place drains in the wound
area. To safely evaluate a new option for reduction of
postoperative complications in mastectomy surgery, how-
ever, this method should be tested against the surgical gold
standard, which is a mastectomy with drain placement.
Risk factors such as radiation treatment, chemotherapy,
smoking habits, increased age and obesity are described in
literature [4, 5, 10–12] and are outside of the control of the
treating physician. Eliminating dead space in the wound
area may, however, be successfully achieved by the sur-
geon. An interesting question is thus to evaluate if mas-
tectomies performed using a surgical gold standard,
including a suction drain, may yield better results when this
adhesive is added.
Patients and methods
A total of 205 breast cancer patients were analyzed in this
study. For patients who received a bilateral mastectomy,
both sides were evaluated individually. This was the case
once in the TissuGlu group and seven times in the control
group. 173 data sets were investigated retrospectively with
regard to age, smoking habits, body mass index (BMI) as
well as prior chemotherapy or previous radiation treatment.
The specific oncological character of each patient will not
be listed in this analysis since histology, grading, staging,
hormone receptor status, etc., does not impact surgical
outcome [13]. The decision to perform unilateral or bilat-
eral mastectomy was always derived from a tumor board.
Thus, gold standards in tumor therapy were adhered to. All
data were collected at the breast cancer center of the Mu-
nicipal Hospital Holweide, Cologne, Germany between
2010 until 2013. The TissuGlu group consisted of con-
secutively enrolled patients in the year 2013. Primary
endpoints were postoperative complication rates, i.e.
seroma formation and severe adverse events. The latter was
considered to have occurred if either re-hospitalization
within 6-month post-surgery became necessary due to
wound healing complications (e.g. infection, deep he-
matoma, wound dehiscence) or in the case of persistent
seroma requiring treatment. Secondary endpoints were
post-surgical superficial hematoma, day of drain removal,
postoperative pain as well as total volume drained.
Surgery and post-surgical management
Naturally, several surgical approaches were available.
Mastectomies were performed with or without axillary
lymph node dissection, possibly in sentinel technique.
Drain placement is common practice in either situation. If
patients received an axillary lymph node dissection along
with a mastectomy, drains would be placed in both areas.
Analysis of the seroma formation focused on the mastec-
tomy area only. All surgeries were performed by the same,
experienced surgical team. The surgical procedure was also
the same for both groups, although the surgical adhesive
was added in the TG group. Figure 1 shows the TissuGlu
application. Equal adhesive droplet placement is ensured
using an adhesive applicator. Following wound closure, the
surface is compressed and immobilized. Compression was
applied by an elastic bandage, wrapped around the thorax,
which was removed after 24 h. The compression regime
was the same for all mastectomy patients. Drains were
placed in all surgical sites, volume drained was recorded
and drains were removed when less than 30 ml/24 h fluid
was recorded, with the exception of the first postoperative
day. Drains remained in place for at least 24 h as standard
in-house protocols demanded. All drains were non-suction
drains.
Post-surgical follow-up for the TG group included reg-
ular clinician wound inspection and an additional pre-dis-
charge inspection as well as a 14-day follow-up. Seroma
formation after drain removal was detected using ultra-
sound and palpation. A bias in favor of the control group
had to be accepted, since only clinically relevant seroma,
i.e. painful, infected, etc., was recorded for these patients,
as they would only revisit our hospital when such problems
occurred. Regular 14-day follow-up was provided in the
control group through their family practitioners. The TG
group, on the other hand, was more closely monitored;
seroma formation was recorded even if not clinically
relevant. To answer the central question of this paper as
conservatively as possible, we accepted this bias towards
the control group so as to not skew results in favor of the
TissuGlu approach.
Informed consent
Written informed consent was obtained from all patients
for publication of this manuscript. A copy of the written
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consent is available for review by the Editor-in-Chief of
this journal. This study was conducted in accordance with
institutional review board standard operating procedures.
Statistics
Statistical analysis was performed using the Vassar Stats
(Vassar College, Poughkeepsie, NY, USA) statistics pro-
gram. Pearson’s Chi squared tests and t tests were used to
evaluate significances when appropriate.
Results
Patient age was similar in both groups. The control group
had a patient age of 62 (±14) years while the con-
secutively recruited TissuGlu group had an average age
of 67 (±13) years (p[ 0.05). Table 1 shows a summary
of all results. BMI, prior chemotherapy and prior radiation
treatment did not differ significantly. The average BMI
was 27 (±7) and 26 (±7) in the control and TG, respec-
tively. Prior radiation therapy was received by ap-
proximately 17 % of the control group patients, and 16 %
of the TG group. Smoking habits differed significantly in
favor of the TG group, where none of the patients listed a
smoking habit, in comparison to the control group where
approximately 14 % smokers were included. With ex-
ception of smoking habits, adequate comparability is thus
given.
Primary endpoint results showed that approximately
16 % of the control group and 28 % of the TG group de-
veloped a postoperative seroma; this difference not being
significant (p[ 0.05). The clinical relevance of this fluid
accumulation should, however, be questioned since 7 % of
the control group patients required revision surgeries or re-
hospitalization and i.v. antibiotic treatment (3 cases) due to
infection, whereas none of the TissuGlu patients required
re-hospitalization at all.
The secondary endpoints showed that superficial postop-
erative hematoma presented in 17 % of the control group
versus 3 % in the TG group (p\ 0.05). No difference was
shown in postoperative pain. Time to drain removal also dif-
fered significantly in favor of the TG group with 4.2 (±1.8)
control groups vs. 3.5 (±1.5) TG days (p\ 0.05). The mean
total amount of fluid collected per patient was also lower the
TG group, although no statistical significance could be
established here. Table 2 shows a subgroup analysis. Inter-
group comparability is given. Distributions do not vary sig-
nificantly for mastectomy-only, mastectomy plus SNL biopsy
and mastectomy plus complete axillary dissection subsets.
Results show adverse events to be evenly distributed within
the control group. No adverse events are found in the TG
group. Seroma formation occurs with the same frequency in
mastectomy-only (48 %) and mastectomy-plus axillary dis-
section (44 %) subsetswithin the control group. This is not the
case in the TG group. Here, 88 % of post-surgical seroma is
found in the mastectomy group. The difference in distribution
is most likely due to small sample size.
Fig. 1 Mastectomy with
sentinel lymph node dissection.
Shown is the surgical situs
during TissuGlu (TG)
application. a the medial
application of adhesive droplets
using the provided TG
applicator. Droplet distribution
was performed in a medial to
lateral manner (b). The white
arrows indicate TG droplets.
c Schematically depicts droplet
spacing on the wound surface.
The red arrow indicates the
droplet spacer. d The wound
cavity from a caudal angle
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Discussion
Study group homogeneity needs to be established before
comparing the two study arms. As patient groups do not
differ in the age, previous radiation and chemo therapy nor
BMI [14], comparison is possible. This was paramount as
these are the most common risk factors for developing
seroma or wound healing complication [4, 5, 9–11].
Smoking habits favored the TG group and future patient
recruitment will have to take this fact into account. Only 3
of the 12 patients with an adverse event in the control
group were smokers.
Primary endpoints
One of the primary endpoints seems to favor the control
group, since approximately 16 % of the control group
developed a post-hospital discharge follow-up seroma
vs. 28 % of the TissuGlu group (p[ 0.05). As these
results do not differ significantly, no definite conclusion
may be drawn at this point. Nonetheless, it is important
to discuss this issue. We may have to accept the possi-
bility that the use of TG may lead to an increase in
postsurgical seroma. This has not been shown or re-
ported in previous literature and should be investigated
in future trials with larger numbers. In addition, a bias in
favor of the control group had to be accepted due to the
retrospective nature of the control group analysis. As
mentioned above, patients of the control group did not
participate in mandatory follow-up visits in our in-house
standard of care. Only clinically relevant seroma, i.e.
patients presenting with pain, discomfort, etc., was
recorded, as these patients returned seeking intervention.
Clinically non-relevant seroma, i.e. painless, small vol-
ume seroma, could not be documented. Since post-sur-
gical follow-up of the TG groups included several
clinical inspections as well as ultrasound analysis of the
immediate post-drain removal situation, non-clinically
relevant seroma formation was in turn documented in
this group. While a comparison between the two groups
Table 1 Summary of seroma
risk factors, primary and
secondary endpoints
Control TissuGlu p value
Total % Total %
n 173 32
Age (years) 62 (±14) 67 (±13) 0.094
BMI 27 (±7) 26 (±7) 0.889
Previous chemotherapy 44 25.4 4 12.5 0.174
Radiation 30 17.3 5 15.6 0.807
Nicotine 24 13.9 0 0.007
Superficial post-surgical hematoma 29 16.8 1 3.1 0.045
Post-surgical pain (1–10) 1.5 (±1) 2,7 (±0, 8) 0.787
Day of drain removal 4.2 (±1.8) 3,5 (±1, 5) 0.008
Total volume 191 (±160) 152 (±116) 0.08
Follow-up seroma 27 15.6 8 27.6 0.06
Adverse events (revision/infection) 12 6.9 0 0.22
Table 2 Subgroup analysis:
intergroup distributions do not
differ significantly with respect
to number of mastectomies.
SNL biopsy and axillary
dissections. Post-surgical
seroma formation occurred
more often in the mastectomy
group for TG
Distribution (% of total) Adverse event (% of total) Seroma (% of total)
Control
Mastectomy 63 (36 %) 5 (38 %) 13 (48 %)
Axilla 79 (46 %) 4 (31 %) 12 (44 %)
SNL 31 (18 %) 4 (31 %) 2 (7 %)
Total 173 13 27
TissuGlu
Mastectomy 14 (44 %) – 7 (88 %)
Axilla 11 (34 %) – –
SNL 7 (22 %) – 1 (13 %)
Total 32 – 8
p 0.223 [0.001
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may nonetheless be drawn, this issue will be addressed
in a follow-up head-to-head prospective study.
Seven percent (n = 12) of the control group experi-
enced a severe adverse event as defined above, and 0 % of
the TissuGlu showed such complications. This supports
the hypothesis above that seroma documented in the TG
group for the primary endpoint may have been clinically
non-relevant. Unfortunately, a significance level could not
be achieved due to small sample number (p[ 0.05).
Secondary endpoints
A recent study investigating a new 50 ml/24 h fluid pro-
duction limit as an indicator for drain removal has
demonstrated this volume to be an adequate and safe pa-
rameter for drain removal [15]. Our study used a limit of
30 ml/24 h which may be viewed as a more challenging
approach to secondary endpoint analysis. Overall, patient
satisfaction (subjectively) was high in the TissuGlu group
due to earlier drain removal: 3.5 days TG versus 4.2 days
in the control group (p\ 0.05). This represents a sig-
nificant decrease in time to drain removal by 17 %.
Although the relevance of this may be theoretical in nature,
the simple fact remains that drains may be removed earlier
without increasing postoperative complication rates.
Although patient satisfaction could not be retrospectively
quantified, drain removal almost always results in a de-
crease in local discomfort, which in turn increases patient
satisfaction. Future analyses will, therefore, attempt to
quantify this aspect. Nonetheless, we are presented with an
option for earlier drain removal when using TG, without
significantly increasing the post-surgical complication rates
[15–17].
Interestingly, post-surgical hematoma was significantly
lower in the TissuGlu  group (3 %) in comparison to the
control group (29 %) (p\ 0.05). This issue will also have to
be addressed in a future prospective study since no hemo-
static properties of TissuGlu are known. Since postop-
erative care was the same, with the exception of the follow-
up visits, this phenomenon could not be explained. One may,
however, speculate that by effectively eliminating dead
space, surface to surface abrasion may be minimized.
Conclusion
This analysis shows that introducing TissuGlu into a
mastectomy area is a useful tool for improving overall
surgical outcome. Non-inferiority could be shown for both
primary endpoints. Follow-up seroma formation and post-
operative adverse events did not differ significantly. A
strong trend towards lower postoperative complication rates
in the TissuGlu group was shown. Secondary endpoints
showed significant improvement in the TissuGlu group
with a 17 % decrease in time to drain removal as well as a
14 % decrease in postoperative hematoma formation.
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